Related Experiment Video

Updated: Aug 18, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Risk assessment of chemicals and pharmaceuticals in the pediatric population: a workshop report

H R Pohl1, J G M van Engelen, J Wilson

  • 1Agency for Toxic Substances and Disease Registry (ATSDR), US Department of Health and Human Services, Atlanta, GA 30333, USA. hpohl@cdc.gov

Regulatory Toxicology and Pharmacology : RTP
|May 18, 2005
PubMed

Insights

This workshop identified knowledge gaps in children's health and chemical risk assessment. It aimed to improve scientifically based risk evaluations for pediatric populations.

Area of Science:

  • Environmental Health
  • Toxicology
  • Pediatric Health

Background:

  • The Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for Public Health and the Environment (RIVM) convened an expert panel.
  • The workshop focused on the differences between children and adults and their implications for risk assessment.

Purpose of the Study:

  • Identify data gaps in scientific knowledge concerning children's health.
  • Recognize areas of mutual interest for future ATSDR/RIVM collaborative projects.
  • Enhance the scientific basis of chemical risk assessment in children.

Main Methods:

  • Expert Panel Workshop format.
  • Discussions on clinical trials and toxicity studies.
  • Exploration of juvenile animal testing and physiologically based pharmacokinetic (PBPK) modeling.

Main Results:

  • Key areas for research in pediatric toxicology were highlighted.
  • The importance of age-specific data for accurate risk assessment was emphasized.
  • Foundational elements for future cooperative research between ATSDR and RIVM were established.

Conclusions:

  • Improved understanding of children's health issues is crucial.
  • Advancements in PBPK modeling and juvenile testing are needed for children's risk assessment.
  • Collaborative efforts are essential to refine scientifically based risk assessments for pediatric populations.

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster07:02

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster

Published on: March 24, 2023

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...